AOXING PHARMACEUTICAL COMPANY, INC.
AXN evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for AXN—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper Score
Based on 3 of 6 signals
Limited data coverage
Market Cap
—
Cash Runway
—
Lead Asset
tilidine (Approved)
Next Catalyst
—
Financial data as of Mar 31, 2017.
Tracking 1 pipeline candidate for AOXING PHARMACEUTICAL COMPANY, INC..
Run AOXING PHARMACEUTICAL COMPANY, INC. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available AOXING PHARMACEUTICAL COMPANY, INC. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Score breakdownBased on 3 of 6 signals · derived from public data
Cash runway data unavailable
D/E 2.27
Lead: Approved
1 candidate
No upcoming catalysts tracked
No insider transactions in the last 180 days
Pipeline
Financials
Governance
Frequently asked questions
What is AOXING PHARMACEUTICAL COMPANY, INC.'s lead drug candidate?
AOXING PHARMACEUTICAL COMPANY, INC.'s most advanced tracked candidate is tilidine (Approved) for acute, moderate to severe pain, and chronic cancer-related pain.
Who is the CEO of AOXING PHARMACEUTICAL COMPANY, INC.?
Zhenjiang Yue is the chief executive officer of AOXING PHARMACEUTICAL COMPANY, INC. (AXN).
What therapeutic areas does AOXING PHARMACEUTICAL COMPANY, INC. focus on?
AOXING PHARMACEUTICAL COMPANY, INC. develops therapies across Oncology, Pain.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.